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ABSTRACT
Objective: The objective of this work was to prepare and optimize orally disintegrating films of acyclovir (ACV), which is a known antiviral agent. To 
enhance the solubility of ACV, solid dispersions of ACV were made.
Methods: The films were prepared using a solvent casting technique. Full factorial design was utilized for the optimization of the effect of independent 
variables such as the amount of hydroxypropyl methylcellulose 5 cps, sodium starch glycolate, and propylene glycol on the disintegration time. Other 
evaluation tests such as drug release, drug content, thickness, and folding endurance of film were also conducted.
Results: Compatibility studies by Fourier transform infrared showed that there was no significant interaction between the drug and excipients used. 
Disintegration time was found to be 43 s for the optimized batch. The in vitro release profile of formulation response disintegrating time in phosphate 
buffer pH 6.8 revealed that there was a significant increment in drug release of the optimized batch in comparison to the screening batches. Further, 
short-term accelerated stability studies carried out for 4 weeks for the optimized formulation which proved that the formulated films were stable at 
the accelerated conditions of temperature and humidity (40±2°C/75±5% RH).
Conclusions: It was concluded that such ACV solid dispersion films could be beneficial in enhancement of dissolution and consequently the oral 
bioavailability of ACV.
Keywords: Acyclovir, Factorial design, Oral disintegrating films, Solid dispersion, Solubility enhancement.
INTRODUCTION
In recent times, there has been an augmented requirement for patient-
compliant dosage forms. Consequently, the demand for innovative 
and patient-friendly dosage forms is forecasted to be the whopping 
US $15,984.3 billion by the end of 2024 up from the US $7,337.8 
million in 2015 [1]. Fast-dissolving dosage forms were initiated in 
the past century in the seventies as a substitute to tablets, capsules, 
and syrups for pediatric and geriatric patients who have trouble 
swallowing conventional oral solid-dosage forms. The popularity of 
oral dosage forms is evidently because of the patient compliance, ease 
in administration, and accurate dosing, price, and superior longevity in 
terms of stability. Oral films are one such patient-friendly dosage forms. 
Fast or rapidly disintegrating film is conveniently placed on the tongue 
where it disintegrates. If it is required, the formulation can be designed 
to quickly disintegrate releasing the medication without delay. This 
would present the drug in a liberated form to the gastrointestinal 
tract where the absorption is quickened. Oral dissolving films have the 
added benefit of not needing a glass of water for administration [2]. 
Orodispersible films have been successfully formulated and evaluated 
for drugs such as metoclopramide [3]. Different polymers have been 
used for making oral films such as hydroxypropyl methylcellulose 
(HPMC) and sodium carboxymethylcellulose [4].
Acyclovir (ACV) is an antiviral agent, which is indicated chiefly for the 
treatment of infection arising due to herpes simplex virus, chickenpox, 
and shingles. ACV is known by its IUPAC name as 2-amino-1,9-dihydro-
9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one [3]. Its half-life is 
reported to be 2–4 h and protein binding to be 9–33%. Water solubility 
is poor at 2.5 mg/ml. In humans, the average oral bioavailability of 
ACV after administration of a 200 mg dose is approximately 20%, and 
this decreases to about 10% with 800 mg dosing [5]. Due to its this 
low oral bioavailability, achievement of plasma concentration sufficient 
for inhibition of the less sensitive herpes simplex virus is not easy 
and intravenous administration may be obligated for better efficacy. 
Solubility enhancement has been positively linked to increased oral 
absorption [5]; hence, in the present research, an attempt has been 
made to improve the solubility of ACV by making ACV solid dispersions 
(ACV-SDs) and formulating ACV-SD into oral films.
MATERIALS AND METHODS
Materials
ACV was a gift sample from Atul Limited, Gujarat, India, mannitol 
purchased from Loba Chemie, Mumbai, India, dimethyl sulfoxide 
(DMSO), polyvinylpyrrolidone K 30, glycerol purchased from Thermo 
Fisher Scientific, Bangalore, India, HPMC 5 cps HPMC K15, ethanol, 
sodium starch glycolate (SSG), propylene glycol, sodium hydroxide, and 
potassium dihydrogen phosphate purchased from SD Fine-Chem Ltd., 
Mumbai, India.
Equipment
Bath sonicator - Sidilu renewable energy, Bangalore, India; Digital 
balance – Ohaus,  India; pH meter - Analytical technologies Ltd., 
Gujarat, India; UV Visible spectrophotometer - Shimadzu, Corporation, 
Japan;  Disintegration apparatus -Electrolab, Mumbai, India;  8-station 
dissolution apparatus, LabIndia disso 8000, India;  Fourier transform-





The solubility of ACV was checked in ethanol, DMSO, water, phosphate 
buffer solution (PBS), and pH 6.8 using the shake-flask technique 
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[6]. Briefly, an excess amount of ACV was added to 5 ml of each 
of the above liquids and shake for 48 h to achieve equilibrium, 
then filtered through Whatman filter paper #1 and analyzed 
spectrophotometrically at λmax 252 nm.
Compatibility studies
The FTIR spectrum of ACV was generated using the potassium pellet 
method. A little quantity of the drugs ACV was intimately mixed with 
potassium bromide (preheated at 105° for 1 h in an oven). Then, the 
mixture was made into a disc using a press machine. The disc was then 
analyzed to generate the FTIR. Similarly, ACV-excipient mixture was 
also studied.
Preparation of solid dispersion
The carrier used was mannitol. Solid dispersion was prepared by 
coevaporation of equimolar ACV - mannitol in dimethyl sulfoxide 
solution on the water bath 70–90°C. Each solid product after 
complete evaporation of solvent used was then scrapped off, 
pulverized, and sieved through 80#. The preliminary trial batch is 
shown in Table 1.
Formulation of blank mouth dissolving films
Formulation trial T4 showed good film-forming properties than 
other formulation; hence, HPMC 5 cps was selected for further film 
formulation.
Formulation of fast disintegrating film of ACV-SD
Weighed amount of film-forming polymer was added to water and 
stirred at a rotation of 100–120 rpm using magnetic stirrer. ACV-SD 
containing equivalent amount of drug (200 mg) was then added into the 
solution with magnetic stirring for 2–3 min at rotation speed of 150–
200 rpm. Other excipients such as plasticizer and superdisintegrant 
were then added one by one with continuous stirring. The solution 
mixture was then slowly poured into a Petri plate, and solvent was 
allowed to evaporate at a temperature of 60°C using hot air oven 
overnight. After solvent was evaporated completely, the strip was 
slowly peeled.
Formulation of screening batch
To identify the vital factors affecting the desired response, a screening 
design was followed. The screening batches were formulated based 
on the definitive screening design done with the help of statistical 
software JMP® 11 by SAS for three factors - the amounts of HPMC (5 
cps), SSG, and glycerol (plasticizer). The design was performed for eight 
experimental runs with the amounts of HPMC 5 cps and SSG ranging 
from 250 to 500 mg and 5 to 20 mg, respectively. These ranges were 
decided based on a prior literature survey. Evaluations of these batches 
were performed the screening batches are shown in Table 2.
Based on the result of screening batches, an optimized formulation 
(Table 3) was designed and evaluated for disintegration time.
Evaluation studies of orally disintegrating films of ACV
Thickness
The thickness of films was measured using screw gauge at three 
different points of the film and an average was taken.
Drug content
2.5 cm2 containing 2.5 mg of ACV was cut evenly and grinded. It was 
then added to 100 ml volumetric flask and diluted using PBS pH 6.8. It 
was then sonicated for 15–20 min. A further dilution was made to Beer’s 
range and the absorbance was measured using UV spectrophotometer 
at 252 nm λmax.
Folding endurance
Area of films (4.5 cm×2.5 cm) was cut evenly and repeatedly folded 
at the same place till it broke. The number of times the films could be 
Table 1: Preliminary trial batches for preparing of blank films
S. No. Ingredients Batches
T1 T2 T3 T4 T5 T6 T7
1 HPMC K15 (mg) 250
2 HPMC M (mg) 250
3 HPMC 100 (mg) 250
4 HPMC 5 cps (mg) 250
5 HPMC E (mg) 250
6 PVP K 30 (mg) 250
7 HPMC 5 cps: HPMC K15 (mg) 250:250
8 Glycerol (mg) 200 200 200 200 200 200 200
9 Vehicle q.s 10 ml Water Water Water Water Water Water Water
HPMC: Hydroxypropyl methylcellulose, PVP: Polyvinylpyrrolidone
Table 2: Screening batches of ACV-SD
S. No. ACV-SD  
(mg)
HPMC 5 cps 
 (mg)




F1 200 250 0.25 20 10
F2 200 500 0.25 20 10
F3 200 500 0.25 5 10
F4 200 250 0.5 20 10
F5 200 250 0.25 5 10
F6 200 250 0.5 5 10
F7 200 500 0.5 5 10
F8 200 500 0.5 20 10
HPMC: Hydroxypropyl methylcellulose, ACV-SD: Acyclovir solid dispersion,
SSG: Sodium starch glycolate
Table 4: Solubility studies of acyclovir and solid dispersion








8 pH 6.8-PD 0.355
DMSO: Dimethyl sulfoxide
Table 3: Optimized formula
S. No. Factor Amount 
1 HPMC 5 cps (mg) 375
2 SSG (mg) 11.912
3 Glycerol (ml) 0.375
HPMC: Hydroxypropyl methylcellulose, SSG: Sodium starch glycolate
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dissolution apparatus) at 37°C using at a rotation speed of 50 rpm. 
5 ml sample was withdrawn at an interval of 5, 15, 30, 45, and 60 min. 
An equal amount of fresh dissolution medium was added back, 
respectively, at each time interval after withdrawal of the test sample. 
Test sample was filtered through Whatman filter paper no 1 and 
suitably diluted. The absorbance of the diluted sample was estimated 




An FTIR spectrum was used to identify if any interaction existed 
between ACV and excipients used. Sample was analyzed by potassium 
bromide pellet method in an IR spectrophotometer (Bruker) in the 
region between 4000 and 400/cm.
Table 5: Evaluation of screening batches
S. No. Code Thickness (µm)±SD (n=3) Folding endurance±SD (n+3) Surface pH±SD (n=3) Disintegration time (S)±SD (n=3)
1 F1 85.66±3.055 84.66±3.68 7.073±0.030 44.33±3.299
2 F2 65.66±2.081 85±3.55 7.4±0.1632 40.33±2.054
3 F3 86.33±2.081 90±4.08 7.33±0.049 49.33±1.699
4 F4 95±2 100±4.082 7.46±0368 37.66±2.054
5 F5 80±2 93±2.160 7.25±0.142 42.66±2.054
6 F6 90.33±2.51 83±2.160 7.46±0.169 50.33±1.699
7 F7 86.66±1.527 92.33±2.35 7.33±0.265 42.33±2.494
8 F8 77.66±1.524 90.33±2.054 7.21±0.0205 52.33±2.054
SD: Standard deviation
Fig. 1: Fourier transform-infrared spectrum of acyclovir (pure drug) after compatibility study
folded the same place without breaking gave the exact value of folding 
endurance.
Disintegration time
A small strip of film is placed in beaker containing 15 ml of phosphate 
buffer pH 6.8 and continuously shaken until the strip disintegrates 
completely.
Surface pH
Surface pH of film was determined by placing the film on the surface 
of 1.5% agar gel followed by placing pH paper (pH range 1–11) on the 
films. The change in the color of pH paper was observed.
In vitro release studies
An area of film containing equivalent amount of ACV (2.5 mg) cm2 
was weighted and added to 900 ml of phosphate buffer pH 6.8 (USP-II 
Fig. 2: Fourier transform-infrared spectrum of acyclovir-excipients after compatibility study
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Short-term accelerated stability studies
Stability studies accelerated were carried out for the optimized 
formulation which was kept at 40°C±2°C/75% RH for 1 month. The 
percentage drug release and drug content were calculated at the end of 
30 days, and FTIR was also recorded.
RESULTS
Table 4 summarizes the data for the solubility studies of ACV-SD. Figs. 1 
and 2 present FTIR spectra for the compatibility study.
Table 5 summarizes the results of the screening batches. Fig. 3 and 
Table 6 present the results of the optimized formulation.
Statistical analysis
Tables 6-16 and Figs. 4-10 deal with the results of optimization.
Optimization
Y=Response disintegration time (s)
Singularity details: Intercept=0.005×Drug (mg)=0.1×Solvent (ml)
The comparative in vitro release profile before and after short-term 
accelerated stability study is presented in Fig. 11, while the FTIR of the 
optimized formulation is shown in Fig. 12.
Table 6: Summary of fit
R2 0.147204
R2 Adj −0.49239
Root mean square error 6.357258
Mean of response 44.9125
Observations (or sum wgts.) 8
Table 7: Analysis of variance
Source DF Sum of squares Mean square F ratio
Model 3 27.90445 9.3015 0.2302
Error 4 161.65890 40.4147 Prob>F
C. Total 7 189.56335 0.8713
Table 8: Parameter estimates
Term Type Estimate Standard error t ratio p>|t|
Intercept Biased 41.243333 10.48894 3.93 0.0171*
Drug (mg) Zeroed 0 0
HPMC 5 (mg) 0.00934 0.017981 0.52 0.6309
Glycerol (ml) 6 17.98104 0.33 0.7554
SSG (mg) −0.166667 0.299684 −0.56 0.6078
Solvent (ml) Zeroed 0 0
HPMC: Hydroxypropyl methylcellulose, SSG: Sodium starch glycolate
Table 9: Sorted parameter estimates
Term Type Estimate Standard error t ratio t ratio p>|t|
SSG (mg) −0.166667 0.299684 −0.56 0.6078
HPMC 5 (mg) 0.00934 0.017981 0.52 0.6309
Glycerol (ml) 6 17.98104 0.33 0.7554
Drug (mg) Zeroed 0 0
Solvent (ml) Zeroed 0 0
HPMC: Hydroxypropyl methylcellulose, SSG: Sodium starch glycolate
Fig. 3: In vitro release studies
Fig. 4: Actual by predicted plot
DISCUSSION
Pure drug had poor solubility of 0.35 mg/ml in PBS pH 6.8; whereas, 
PD-SD has significantly improved solubility of 29.64 mg/ml in PBS 
pH 6.8. This may be due to the effect of the carrier mannitol which was 
can be explained by configuration of areas containing elevated levels 
of dissolved mannitol at the surface of drug crystals in which the 
drug may be solubilized [7,8]. Hence, it will advance the consequent 
diffusion of ACV followed by dilution in the mass of the solution. As 
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peaks of ACV were evident in the FTIR of mixture of ACV and other 
excipients, it proved that ACV was compatibility with the excipients. 
FTIR of pure drug ACV showed its characteristic major peaks (cm−1) 
at 3524:OH stretching; 3439:NH2 stretching; 3278:C-H aliphatic 
stretching; 1713:C=O stretching; and 778:C=H rocking. The FTIR 
spectra for drug-excipient compatibility study revealed no interaction 
between ACV and excipient (HPMC-5 and SSG) as evident by the main 
bands (cm−1) of ACV at 3524:O-H overlapping; 3439:NH2 stretching; 
3278:C-H aliphatic stretching; 1713:C=O stretching; and 778:C=H 
rocking. Drug content for screening batches prepared was to be 
found lowest for F1 (87%±0.0084) and highest for F4 (95%±0.0123). 
Fig. 5: Prediction profiler
Thickness of the formulations was found to be lowest for F2 (65.66 
µm±2.08) and highest for F4 (95 µm±2). Folding endurance for film 
formulation was found to be lowest for F6 (83±2.160) and highest 
Table 11: Analysis of variance
Source DF Sum of squares Mean square F ratio
Model 3 15540.104 5180.03 32.9301
Error 5 786.521 157.30 p>F
C. Total 8 16326.625 0.0010*
Tested against reduced model: Y=0
Table 12: Parameter estimates
Term Estimate Standard error t ratio p>|t|
HPMC 5 (mg) 0.0547918 0.027173 2.02 0.0998
Glycerol (ml) 51.451837 27.1729 1.89 0.1168
SSG (mg) 0.2541837 0.552248 0.46 0.6646
HPMC: Hydroxypropyl methylcellulose, SSG: Sodium starch glycolate
Table 13: Summary of fit
R2 0.147204
R2 Adj −0.49239
Root mean square error 6.357258
Mean of response 44.9125
Observations (or sum wgts.) 8
Table 14: Analysis of variance
Source DF Sum of squares Mean square F ratio
Model 3 27.90445 9.3015 0.2302
Error 4 161.65890 40.4147 p>F
C. Total 7 189.56335 0.8713
Table 15: Parameter estimates
Term Estimate Standard error t ratio p>|t|
Intercept 41.243333 10.48894 3.93 0.0171*
HPMC 5 (mg) 0.00934 0.017981 0.52 0.6309
Glycerol (ml) 6 17.98104 0.33 0.7554
SSG (mg) −0.166667 0.299684 −0.56 0.6078
HPMC: Hydroxypropyl methylcellulose, SSG: Sodium starch glycolate
Fig. 6: Contour profiler
Fig. 7: Whole model actual by predicted plot
Table 10: Summary of fit
R2
R2 Adj
Root mean square error 12.54209
Mean of response 44.9125
Observations (or sum wgts.) 8
Whole model
285
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 280-286
 Pandey and Khan 
for F4 (100±4.08). Disintegration time was found to be lowest for 
F4 (37.66±2 s) and highest for F8 (52±2 s). Surface pH was found 
to be lowest for F1 (7.07±0.0309) and highest for F4 (7.466±0.36). 
Percentage CDR of screening batches was found to be lowest for 
F1 (46.04%±0.00124) and highest for F4 (96.12%±0.00124). Drug 
content for optimized formulation was found to be 97.13% ±0.0044. 
Percentage CDR was found to be 96.89%±0.0033 may be due to 
rapid uptake of water, followed by rapid and enormous swelling of 
SSG. Thickness of film formulation was found to be 90 µm±1.639 
and folding endurance was found to be 103.33±6.23. Surface pH 
of film formulation was found to be 7.46±0.133 and disintegration 
time of films formulation was found to be 43±1.6329 s (predicted: 
42.8 s). Thus, the actual value of the disintegration time was in close 
agreement with the predicted value. Post short-term accelerated 
stability studies showed that ACV remained stable as evident by 
the peaks shown in the FTIR (Fig. 5); also, the percentage CDR was 
recorded at 93.36% which was close to the original value of 96.12%.
CONCLUSION
As the solubility profile of ACV-SD showed an improvement, it was 
concluded that such ACV-SD could be beneficial in enhancement of 
dissolution and consequently the oral bioavailability of ACV. The 
optimized oral films of ACV-SD were rapidly disintegrating indicating 
the success of this research work. Future scope of the study would be 
to study its effectiveness and safety in animals and humans followed 
by scale-up.
Fig. 8: Residual by predicted plot
Fig. 9: Hydroxypropyl methylcellulose 5 (mg) leverage plot
Fig. 10: Glycerol (ml) leverage plot
Fig. 11: In vitro release profile of the optimized formula before 
and after short-term accelerated stability study
Fig. 12: Fourier transform-infrared spectrum of the optimized 
formula after short-term accelerated stability study













97.13±0.0044 90±1.632 7.46±0.133 103±6.23 42.86 43±1.632
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